Skip to content

Role of vitamin D supplementation in chronic urticaria patients

Efficacy and Safety of Vitamin D supplementation in patients of Chronic Spontaneous Urticaria - nil

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/08/056420
Enrollment
62
Registered
2023-08-11
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: L509- Urticaria, unspecified

Interventions

Intervention1: Group 1 patients receiving only tab levocetirizine: 31 patients will receive Tab levocetirizine 5 mg once daily initially with subsequent increment as per patient requirement upto maxim

Sponsors

Dr Disha Chakraborty
Lead Sponsor
Dr Abhishek De
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patient of chronic spontaneous urticaria presenting in the outpatient department of Dermatology.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
1. There can be altered levels of serum vitamin D in the patients of CSU when compared to age-matched healthy control at baseline. 2. There can be correlations of serum vitamin D levels with disease severity & duration at baseline, 4 weeks, 8 weeks. 3. There can be a difference in disease control (UAS7 score and) tablet score between the two groups at baseline, 4 weeks and the end of 8 weeks. Timepoint: 1. There can be altered levels of serum vitamin D in the patients of CSU when compared to age-matched healthy control at baseline. 2. There can be correlations of serum vitamin D levels with disease severity & duration at baseline, 4 weeks, 8 weeks. 3. There can be a difference in disease control (UAS7 score and) tablet score between the two groups at baseline, 4 weeks and the end of 8 weeks.

Secondary

MeasureTime frame
Is there any correlations of serum vitamin D levels with disease severity & duration. Is there can be a difference in disease control (UAS7 score and) tablet score between the two groups at the end of 8 weeks? Timepoint: 8 weeks

Countries

India

Contacts

Public ContactDisha Chakraborty

Calcutta National Medical College and Hospital

dr_abhishek_de@yahoo.co.in9903275551

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026